Share Email Print

Proceedings Paper

Skin imaged by femtosecond laser irradiation: a risk assessment for in vivo applications
Author(s): F. Fischer; B. Volkmer; S. Puschmann; R. Greinert; W. Breitbart; J. Kiefer; R. Wepf
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

During the last couple of years new imaging techniques using femtosecond lasers (fs-lasers) in the near infrared spectral range evolved for a variety of in vitro applications. We wanted to know, whether fs-lasers have a non-invasive imaging potential for in vivo applications for human skin. So far, little is known about possible risks of this irradiation type. To estimate the risk of irradiation damage in human skin we used a "biological dosimeter" in this investigation. We irradiated fresh human skin samples with both an fs-laser and a solar simulator (UV-source) for comparison. DNA damage introduced in the epidermis was evaluated using fluorescent antibodies against cyclobutane-pyrimidin-dimers (CPDs) in combination with immuno-fluorescence image analysis. Various fs-irradiation regimes were evaluated differing in laser power and step width of horizontal irradiation scans. When using 15 mW or 30 mW fs-laser power combined with horizontal irradiation scans applied every 5 mm in depth around the epidermal-dermal junction no induction of CPDs was found. However, induction of CPDs could be seen using 60 mW laser power and 5 μm step width. Narrowing the step width to 1 mm and using increasing laser power (up to 35 mW) from the surface of the skin to the epidermis led to CPD formation, too. Quantitative comparison of CPD production at various laser regimes with CPD production using a solar simulator was done. We could show that the number of CPDs formed by the 60 mW laser irradiation regime is comparable to an UV-irradiation giving 0.6 MED (minimal erythemal dose). The smaller step width laser irradiation regime (1 μm step width and up to 35 mW) was comparable to a UV-irradiation regime resulting in 0.45 MED.

Paper Details

Date Published: 14 April 2006
PDF: 8 pages
Proc. SPIE 6191, Biophotonics and New Therapy Frontiers, 619105 (14 April 2006); doi: 10.1117/12.662600
Show Author Affiliations
F. Fischer, Beiersdorf AG (Germany)
B. Volkmer, Dermatologisches Zentrum Buxtehude (Germany)
S. Puschmann, Beiersdorf AG (Germany)
R. Greinert, Dermatologisches Zentrum Buxtehude (Germany)
W. Breitbart, Dermatologisches Zentrum Buxtehude (Germany)
J. Kiefer, Univ. Giessen (Germany)
R. Wepf, Beiersdorf AG (Germany)

Published in SPIE Proceedings Vol. 6191:
Biophotonics and New Therapy Frontiers
Romualda Grzymala; Olivier Haeberle, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?